Jose Luis Estela-Zape , Valeria Sanclemente-Cardoza , Leonardo Arzayus-Patiño , Lizeth Dayana Noreña-Buitrón , María Alejandra Espinosa
{"title":"Rhabdomyosarcoma in adults with severe thrombocytopenia: Challenges in clinical management and therapeutic complications","authors":"Jose Luis Estela-Zape , Valeria Sanclemente-Cardoza , Leonardo Arzayus-Patiño , Lizeth Dayana Noreña-Buitrón , María Alejandra Espinosa","doi":"10.1016/j.rmcr.2025.102211","DOIUrl":"10.1016/j.rmcr.2025.102211","url":null,"abstract":"<div><div>Alveolar rhabdomyosarcoma (ARMS) in adults is a rare condition with a poor prognosis compared to other subtypes. The management of this pathology is complex due to the lack of standardized guidelines and the limited response to multimodal treatments, including chemotherapy, radiotherapy, and surgery. We report the case of a 40-year-old male with stage IV ARMS and pulmonary metastasis, who underwent resection of right supraclavicular sarcoma and cervical lymph node dissection. He was later referred for palliative chemotherapy following an acute clinical presentation lasting two days, characterized by right facial edema, inflammation, ulceration, and severe pain. Initial treatment included ampicillin/sulbactam, trimethoprim/sulfamethoxazole, and dexamethasone. Chemotherapy with doxorubicin and ifosfamide was delayed due to thrombocytopenia, elevated D-dimer and fibrinogen levels, and an echocardiographic finding that required differentiation between thrombus and metastatic lesion. Anticoagulation with fondaparinux and transfusions were initiated, and the patient received 10 sessions of radiotherapy. During hospitalization, the patient developed orthopnea, pleural effusion, superior vena cava syndrome, and hemodynamic deterioration, necessitating vasopressor support and mechanical ventilation. Despite these interventions, the patient progressed to refractory shock, severe hypoxemia, and died from cardiac arrest. This case highlights the challenges in managing ARMS in adults with severe thrombocytopenia.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"55 ","pages":"Article 102211"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Erythrocytosis as an indicator of disease progression of small cell lung cancer: A case report","authors":"Takuya Tanaka, Yutaka Takahara, Ryudai Abe, Nagae Sumito, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Masafumi Nojiri, Masaharu Iguchi","doi":"10.1016/j.rmcr.2025.102240","DOIUrl":"10.1016/j.rmcr.2025.102240","url":null,"abstract":"<div><div>This case involves a 62-year-old male diagnosed with extensive-stage small cell lung cancer (ES-SCLC) originating from the right lower lobe with brain metastases. The patient underwent stereotactic radiosurgery (SRS) and received four cycles of combination therapy with cisplatin, etoposide, and durvalumab, followed by maintenance therapy with durvalumab to achieve disease control. On day 156 after treatment initiation, hemoglobin (Hb) levels increased to 16.9 g/dL, indicating polycythemia. Concurrently, new brain metastatic lesions were identified, and serum erythropoietin (EPO) levels were markedly elevated at 406 mIU/mL. Whole-brain radiation therapy (WBRT) was initiated, resulting in a subsequent reduction in hemoglobin levels and improvement in polycythemia. This report describes a rare case of secondary polycythemia associated with ES-SCLC. Notably, WBRT appeared to contribute to the normalization of serum EPO levels and resolution of polycythemia. This report elucidates the clinical course and relevance of this condition based on a literature review.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"56 ","pages":"Article 102240"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144137983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Lethal Case of Acute Exacerbation of Rheumatoid Arthritis – Related Interstitial Lung Disease Induced by the COVID Vaccine.","authors":"Rayan Mohamad, Rami Hallak, Imad Bou Akl, Hisham Bou Fakhreddine","doi":"10.1016/j.rmcr.2023.101959","DOIUrl":"10.1016/j.rmcr.2023.101959","url":null,"abstract":"<div><p>Interstitial lung disease (ILD) exacerbation is a serious condition that can have a high morbidity and mortality. Identifying the triggers of ILD exacerbations is very challenging. Several case reports described COVID-19 vaccine-induced exacerbation of underlying interstitial lung disease, namely idiopathic interstitial pneumonias. The clinical implications of this adverse effect is underrecognized. We are reporting a case of fatal respiratory failure in a patient with rheumatoid arthritis Interstitial Lung disease few days following the second dose of COVID vaccine. Identifying risk factors of this complication is of utmost importance to aid in the rapid recognition and early initiation of treatment.</p></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"48 ","pages":"Article 101959"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213007123001545/pdfft?md5=ad15690552118024433c7403ca2be334&pid=1-s2.0-S2213007123001545-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138991451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlos Felipe Arias-Osorio , Heiler Lozada-Ramos , Jorge Enrique Daza-Arana , Luis Miguel Osorio-Toro , Diana Marcela Bonilla-Bonilla
{"title":"Varicella pneumonia in an immunocompetent adult patient: Case report and review of the literature","authors":"Carlos Felipe Arias-Osorio , Heiler Lozada-Ramos , Jorge Enrique Daza-Arana , Luis Miguel Osorio-Toro , Diana Marcela Bonilla-Bonilla","doi":"10.1016/j.rmcr.2024.102112","DOIUrl":"10.1016/j.rmcr.2024.102112","url":null,"abstract":"<div><div>Varicella is a childhood disease characterized by its self-limiting and benign nature. However, it can also affect the adult population due to risk factors, leading to infection with numerous complications involving the central nervous system, kidneys, respiratory system, and skin. Varicella pneumonia, one of the most feared complications in adults, occurs in approximately 1 out of 400 patients with the disease. This complication primarily affects male patients with a history of heavy smoking and immunosuppression, either due to an underlying disease such as HIV and cancer, drug use, pregnancy or pulmonary disease. It is recommended that this complication should be treated with intravenous acyclovir at a dose of 10 mg/kg/8 hours. The prognosis depends on the development of respiratory failure; up to 50 % of patients with this complication require invasive mechanical ventilation. Here, we report the clinical case of an immunocompetent patient with a typical presentation of varicella that rapidly progressed to a respiratory infection requiring antiviral treatment and invasive mechanical ventilation.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"52 ","pages":"Article 102112"},"PeriodicalIF":0.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment of intractable bronchopleural fistula with a one-side-closed silicone stent using retrograde approach: A case report","authors":"Masaya Tamura, Naoki Furukawa, Marino Yamamoto, Ryohei Miyazaki, Hironobu Okada","doi":"10.1016/j.rmcr.2024.102134","DOIUrl":"10.1016/j.rmcr.2024.102134","url":null,"abstract":"<div><div>A male patient (age: 85 -years) with lung cancer underwent basal segmentectomy. Subsequently, he underwent emergency open window thoracotomy for a bronchial stump fistula. The general and nutritional conditions of the patient improved; nevertheless, natural closure of the fistula did not occur. Therefore, the patient underwent fistula closure using an endobronchial Watanabe spigot, polyglycolic acid sheet and N-butyl-2-cyanoacrylate. Nine months later, the fistula had enlarged. The air leak was treated by applying pressure with gauze; however, this approach was not sufficiently effective, and the patient became unable to expectorate phlegm or speak. One side of a straight-type silicone stent with an outer diameter measuring 9mm was closed, and the stent was inserted into the fistula through the fenestration with the closed side at the tip. The L-sized endobronchial Watanabe spigot was placed into the lumen of the stent to reinforce it. Air leak from the fistula was significantly reduced, making breathing and expectoration easier. Retrograde closure of a bronchial fistula using a unilaterally closed silicon stent can be an effective treatment for large, refractory bronchial fistulas.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"52 ","pages":"Article 102134"},"PeriodicalIF":0.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142537529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pulmonary interstitial glycogenosis in two neonates: Early recognition and use of corticosteroids","authors":"Eric Hamberger , Yolanda Yu , Hyo-Jung Choi","doi":"10.1016/j.rmcr.2024.101990","DOIUrl":"https://doi.org/10.1016/j.rmcr.2024.101990","url":null,"abstract":"<div><p>Pulmonary interstitial glycogenosis (PIG) is known to be associated with a wide variety of congenital conditions, though the extent to which PIG contributes to clinical presentation and outcomes in infants remains controversial. We describe two cases of infants with congenital anomalies and respiratory distress at birth who were diagnosed with PIG with differing clinical courses and response to methylprednisolone therapy. These cases highlight the importance of improved recognition of PIG and uncertainties about which patients may benefit from treatment.</p></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"48 ","pages":"Article 101990"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213007124000133/pdfft?md5=122c84234955f0af4d875cd0d08a6067&pid=1-s2.0-S2213007124000133-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139675755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Xanthogranulomatous pleuritis induced by recurrent biliothorax due to a biliopleural fistula: The first case report in the literature","authors":"Moatasem Hussein Al-janabi , Hussein Kaada , Ghina Ismail , Dommar Roumieh , Zuheir Al-Shehabi","doi":"10.1016/j.rmcr.2024.102065","DOIUrl":"https://doi.org/10.1016/j.rmcr.2024.102065","url":null,"abstract":"<div><p>Xanthogranulomatous pleuritis is an extremely rare pathological entity, characterized by the infiltration of foamy cells and multinucleated giant cells within the pleural space. This condition often mimics infectious and neoplastic processes, presenting significant diagnostic challenges. This report details the first documented case of xanthogranulomatous pleuritis induced by recurrent biliothorax due to a biliopleural fistula, presenting a unique clinical scenario. We describe the clinical presentation, diagnostic hurdles, and both the surgical and medical management of this case. The discovery of biliothorax, evidenced by pleural fluid bilirubin levels that exceed serum bilirubin levels, underscores the importance of considering biliothorax in the differential diagnosis of recurrent pleural effusions, particularly in patients with a history of trauma. This case emphasizes the need for heightened awareness and a multidisciplinary approach in the diagnosis and treatment to effectively manage this complex condition and prevent recurrence.</p></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"50 ","pages":"Article 102065"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213007124000881/pdfft?md5=360bfb07ca3bd5d990d0df0e8ad11ee5&pid=1-s2.0-S2213007124000881-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ning Cui, Jingluan Wang, Yanmei Shao, Jingming Zhao, Zhaozhong Cheng
{"title":"Combined allergic bronchopulmonary mycosis and eosinophilic granulomatosis with polyangiitis: A case report and literature review","authors":"Ning Cui, Jingluan Wang, Yanmei Shao, Jingming Zhao, Zhaozhong Cheng","doi":"10.1016/j.rmcr.2024.102012","DOIUrl":"https://doi.org/10.1016/j.rmcr.2024.102012","url":null,"abstract":"<div><p>A 27-year-old female visited our hospital with a history of asthma, peripheral blood eosinophilia, increased total IgE, Aspergillus fumigatus specific IgE, reversible mild bronchiectasis, sinusitis, bronchial mucus plugs and cultivation of Aspergillus from BALF. Glucocorticoids therapy is effective. These results met the diagnostic criteria for both allergic bronchopulmonary aspergillosis (ABPM) and eosinophilic granulomatosis with polyangiitis (EGPA). Special attention should be paid to the possibility of both diseases coexisting in the disease process.</p></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"48 ","pages":"Article 102012"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213007124000352/pdfft?md5=7055953510f9afe5cb8ef7d7df3a9401&pid=1-s2.0-S2213007124000352-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140179899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ravi Manglani , Ji-Hae Shin , Venkata Sireesha Chemarthi , Mohamad Raji , Anna Rozenshtein , Oleg Epelbaum
{"title":"Barking up the wrong tree: Vascular tree-in-bud due to intravascular lymphoma","authors":"Ravi Manglani , Ji-Hae Shin , Venkata Sireesha Chemarthi , Mohamad Raji , Anna Rozenshtein , Oleg Epelbaum","doi":"10.1016/j.rmcr.2024.102020","DOIUrl":"https://doi.org/10.1016/j.rmcr.2024.102020","url":null,"abstract":"<div><p>A 59-year-old previously healthy woman presented with a six-month history of fever, nonproductive cough, and weight loss. The cause of these symptoms remained obscure despite a thorough, month-long hospitalization. On presentation, she was normotensive with a pulse of 98 beats/minute, respiratory rate of 20 breaths/minute, and a temperature of 39.4C. She was emaciated. Physical examination was notable for faint bibasilar crackles on lung auscultation. Initial laboratory testing revealed pancytopenia. Peripheral smear demonstrated normocytic, normochromic anemia without immature cells or schistocytes. Other notable laboratory findings included elevated levels of lactate dehydrogenase, elevated ferritin, and elevated levels of fasting serum triglycerides. A comprehensive laboratory evaluation for connective tissue disease was negative. Plain chest radiography was normal while computed tomography (CT) of the chest demonstrated sub-centimeter nodules in a branching centrilobular pattern as well as in a peri-lymphatic distribution without associated lymphadenopathy or organomegaly.</p><p>The above constellation of laboratory abnormalities raised concern for hemophagocytic lymphohistiocytosis (HLH). Soluble IL-2 (CD25) receptor levels were markedly elevated. Bronchoscopy with transbronchial biopsies of the right lower lobe was performed, revealing intravascular lymphoma associated with HLH. Our case emphasizes the need for clinicians to consider vascular causes of tree - in-bud nodules in addition to the conventional bronchiolar causes. The case also is a reminder of the need to conduct an exhaustive search for malignancy, in patients with HLH.</p></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"49 ","pages":"Article 102020"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213007124000431/pdfft?md5=40399c3fca7ea488c175d8a671e7e605&pid=1-s2.0-S2213007124000431-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140605564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vahdatpour C , Saha B , Younis M , Montuoro C , Timofte I , Rackauskas M , Emtiazjoo A
{"title":"A case report of a lung transplant recipient receiving belatacept in combination with low dose tacrolimus complicated by progressive multifocal leukoencephalopathy","authors":"Vahdatpour C , Saha B , Younis M , Montuoro C , Timofte I , Rackauskas M , Emtiazjoo A","doi":"10.1016/j.rmcr.2024.102028","DOIUrl":"https://doi.org/10.1016/j.rmcr.2024.102028","url":null,"abstract":"<div><p>Belatacept is a novel T-cell costimulation blockade agent that has unresolved controversy in lung transplant recipients. Belatacept has been recognized as a calcineurin sparing agent for solid organ transplant recipients after reported success in renal transplant patients, despite limited evidence in other transplant recipients. We present the first case of a lung transplant recipient receiving Belatacept, in combination with low dose calcineurin inhibitor, who developed progressive multifocal leukoencephalopathy. While Belatacept without calcineurin inhibitor has been associated with increased risk of acute rejection in solid organ transplant recipients, its infectious risk profile in combination with calcineurin inhibitor remains unclear.</p></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"49 ","pages":"Article 102028"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213007124000510/pdfft?md5=c05bfdc3c0aef8182f59d5edca6397e1&pid=1-s2.0-S2213007124000510-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140816321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}